Allos Therapeutics, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 3 Calls Today's Calls

Call Details Allos Therapeutics, Inc. Earnings Conference Call (Q3 2009) Tue, Nov 3, 2009, 4:30 pm Eastern Listen to the archived event audio About Allos Therapeutics, Inc. (NasdaqGM:ALTH) Other Calls  Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumulates preferentially in cancer cells and treats patients with relapsed or refractory peripheral T-cell lymphoma. The company also offers RH1, a small molecule chemotherapeutic agent, which is under Phase I trial to treat patients with advanced solid tumors and non-Hodgkin’s lymphoma. In addition, it is evaluating Pralatrexate in various Phases for the treatment of non-Hodgkin's Lymphoma and Hodgkin's disease, cutaneous T-cell lymphoma, non-small cell lung cancer, bladder cancer, and other solid tumor indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings